BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Freneslerbart/mevonlerbart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Freneslerbart/mevonlerbart\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07675811-3914@assetmemo.bio
DTSTAMP:20261121T004113Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Freneslerbart/mevonlerbart: Phase 3 readout est. (NCT07675811)
DESCRIPTION:Freneslerbart/mevonlerbart\, phase 3\, Allergic Conjunctivitis.
 \nStudy: A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal
  Antibodies in Adult and Pediatric Participants With Allergic Conjunctivit
 is Due to Cat Allergy\nEstimated primary completion: 31 May 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/freneslerbart-mevonlerbart#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076758
 11
URL:https://assetmemo.bio/drug/freneslerbart-mevonlerbart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
